We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Actions that trial sponsors should consider to build resilience into clinical trial design
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
How investigators and sponsors should manage clinical trials during COVID-19
How to show MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.
Information about when you need to submit substantial amendments to a clinical trial including changes to the trial sponsor or legal representative, Investigational medicinal product certification and importation.
This study assessed the care of hypertension, diabetes and HIV patients in Medication Adherence Clubs in Kibera, Nairobi
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
The MHRA is ready to provide any assistance for clinical trials applications submitted for COVID-19
This systematic review is the first to describe the evidence base for MSSS models of care and highlight the current limitations of available research.
How to use a factorial randomised controlled trial to evaluate your digital health product.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
How to get scientific advice about your licence application from MHRA, including: submitting a request, your meeting with MHRA, fees.
Directory of current ICH Guidelines which have been implemented by the Medicines and Healthcare products Regulatory Agency.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).